From the Research
Neither albuterol nor Trelegy (fluticasone furoate/umeclidinium/vilanterol) is typically associated with elevated platelet counts as a common side effect. Elevated platelets, known as thrombocytosis, are more commonly associated with inflammatory conditions, infections, iron deficiency anemia, certain cancers, or as a response to acute bleeding or surgery 1. While respiratory medications can cause various side effects, changes in platelet counts are not typically among them for these specific medications. Albuterol is a short-acting beta-agonist that primarily affects the respiratory system by relaxing airway muscles, while Trelegy combines an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-agonist to treat COPD or asthma.
Some studies have discussed the management of thrombocytosis, emphasizing the importance of identifying the underlying cause and individualizing treatment based on the patient's thrombotic and bleeding risks 2, 1. However, these discussions are more relevant to conditions like essential thrombocythemia or reactive thrombocytosis rather than the side effects of respiratory medications. The most recent study provided, from 2022, focuses on patient experiences with Trelegy compared to other inhalers, highlighting symptoms, adherence, and medication beliefs, but does not mention platelet counts or thrombocytosis as an issue 3.
If you're experiencing elevated platelets while taking these medications, it's crucial to consult with your healthcare provider to investigate other potential causes, as the elevated platelet count is likely unrelated to these respiratory medications and may require further evaluation to determine the underlying cause. This approach prioritizes the patient's health and safety, ensuring that any potential risks associated with thrombocytosis are managed appropriately.